Amphastar Pharmaceuticals (AMPH) EBT Margin (2013 - 2026)

Amphastar Pharmaceuticals' EBT Margin history runs 14 years deep, the most recent figure standing at 5.87% for Q1 2026.

• On a quarterly basis, EBT Margin fell 1223.0% year-over-year to 5.87% in Q1 2026; TTM through Mar 2026 was 14.27%, a 937.0% decrease from a year earlier, with the FY2025 full-year figure at 17.17%, down 875.0% from the prior year.
• EBT Margin eased to 5.87% in Q1 2026 per AMPH's latest filing, from 17.43% in the prior quarter.
• Across five years, EBT Margin topped out at 35.25% in Q3 2023 and bottomed at 78.93% in Q4 2023.
• The 5-year median for EBT Margin is 22.55% (2025), against an average of 16.12%.
• Across the five-year window, EBT Margin slumped 10949 bps in 2023 and soared 10250 bps in 2024, its largest moves.
• Year by year, EBT Margin stood at 30.56% in 2022, then slumped by 358 bps to 78.93% in 2023, then surged by 130 bps to 23.57% in 2024, then decreased by 26 bps to 17.43% in 2025, then plunged by 66 bps to 5.87% in 2026.
• Per Business Quant, the three latest AMPH EBT Margin figures stand at 5.87% (Q1 2026), 17.43% (Q4 2025), and 11.21% (Q3 2025).